Clinical Research Directory
Browse clinical research sites, groups, and studies.
CORRECT Study of Minimal Residual Disease Detection in Colorectal Cancer
Sponsor: Exact Sciences Corporation
Summary
The CORRECT - MRD II study will prospectively enroll patients who have undergone complete surgical resection for stage II or III colorectal cancer. Maximum duration of participant participation is up to seven years from enrollment to study completion with up to five years of active follow up and up to two years of clinical (passive) follow up.
Official title: CORRECT-MRD II: Second Colorectal Cancer Clinical Validation Study to Predict Recurrence Using a Circulating Tumor DNA Assay to Detect Minimal Residual Disease
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
1017
Start Date
2021-12-15
Completion Date
2027-05-15
Last Updated
2026-01-12
Healthy Volunteers
No
Conditions
Interventions
MRD
ctDNA MRD test
Locations (32)
Facey Medical Group - Mission Hills - Endoscopy Center & Gastroenterology
Mission Hills, California, United States
Torrance Memorial Hunt Cancer Institute
Torrance, California, United States
University of Florida Division of Hematology & Oncology
Gainesville, Florida, United States
Mount Sinai Medical - Comprehensive Cancer Center
Miami Beach, Florida, United States
Mid Florida Cancer Centers
Orange City, Florida, United States
Edward Cancer Center
Elmhurst, Illinois, United States
Illinois Cancer Care
Peoria, Illinois, United States
Mercy Medical Center
Cedar Rapids, Iowa, United States
University of Kansas Cancer Center
Westwood, Kansas, United States
MedStar Georgetown Cancer Institute at MedStar Georgetown University Hospital
Baltimore, Maryland, United States
Meritus Center for Clinical Research
Hagerstown, Maryland, United States
University of Maryland St. Joseph Medical Center
Towson, Maryland, United States
Metro Minnesota Community Oncology Consortium (MMCORC)
Saint Louis Park, Minnesota, United States
Missouri Baptist Medical Center
St Louis, Missouri, United States
Atrium Health Levine Cancer Institute
Charlotte, North Carolina, United States
FirstHealth Outpatient Cancer Center
Pinehurst, North Carolina, United States
Atrium Health Wake Forest Baptist Medical Center
Winston-Salem, North Carolina, United States
Sanford Roger Maris Cancer Center
Fargo, North Dakota, United States
Columbus NCORP
Columbus, Ohio, United States
Interstate Medical Office Central
Portland, Oregon, United States
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, United States
Reading Hospital Hematology Oncology
West Reading, Pennsylvania, United States
Lankenau Medical Center
Wynnewood, Pennsylvania, United States
WellSpan York Cancer Center
York, Pennsylvania, United States
Primsa Health Cancer Institute
Greenville, South Carolina, United States
Sanford Cancer Center
Sioux Falls, South Dakota, United States
Ballad Health Cancer Center
Kingsport, Tennessee, United States
Marshfield Medical Center Weston
Weston, Wisconsin, United States
Cross Cancer Institute
Edmonton, Alberta, Canada
Princess Margaret Cancer Center
Toronto, Ontario, Canada
Jewish General Hospital
Montreal, Quebec, Canada
McGill University Health - Glen Site
Montreal, Quebec, Canada